SEDAR Information
Read about Tryp Therapeutics on Sedar
All News
See below for a comprehensive list of news items published by Tryp Therapeutics.
Tryp Therapeutics Announces 99.92% Votes Cast By Shareholders In Favor Of Arrangement Agreement At Annual General And Special Meeting Of Securityholders, And Receipt Of Final Order
March 12, 2024 Kelowna, Canada – March 12, 2024 – Tryp Therapeutics, Inc. (“Tryp” or the “Company”) (CSE: TRYP, OTCQB:…
Tryp Therapeutics And Exopharm Limited Secure Pivotal 2 Cent Waiver From ASX
January 26, 2024 Kelowna, Canada – January 26, 2024 – Tryp Therapeutics, Inc. (“Tryp” or the “Company”) (CSE: TRYP, OTCQB:…
Tryp Therapeutics Announces Significant Milestone In Its Clinical Trial Program For Trp[1]8803 (Iv-Infused Psilocin)
January 8, 2024 Kelowna, Canada – January 8, 2024 – Tryp Therapeutics, Inc. (“Tryp” or the “Company”) (CSE: TRYP,OTCQB: TRYPF),…
Tryp Therapeutics Announces First Patient Dosed In Phase 2a Clinical Trial For The Treatment Of Fibromyalgia At The University Of Michigan
January 4, 2024 Kelowna, Canada – January 4, 2024 – Tryp Therapeutics Inc. (“Tryp” or the “Company”) (CSE: TRYP), a…
Tryp Therapeutics Inc. Announces Signing of Definitive Agreement with Exopharm Limited
DECEMBER 13, 2023 KELOWNA, BC / ACCESSWIRE / December 11, 2023 / Tryp Therapeutics Inc. (“Tryp” or the “Company“) (CSE:TRYP), a…
Tryp Therapeutics Announces Closing of Oversubscribed Private Placement of Unsecured Convertible Notes for Gross Proceeds of AUD$3,215,000
January 8, 2024 Kelowna, Canada – January 8, 2024 – Tryp Therapeutics, Inc. (“Tryp” or the “Company”) (CSE: TRYP, OTCQB:…